Reach Millions. Build Your Brand
AROGYAM · NSE · Healthcare · Pharmaceuticals
₹1,812.65
+27.35(+1.53%)Updated 25 Sept 2026, 9:52 am · Real-time
NSE
₹1,812.65
BSE
₹1,813.56
Last 30 trading sessions (14 Aug 2026 – 24 Sept 2026)
Open
₹1,790.00
Previous Close
₹1,785.30
Day Range
₹1,786.00 – ₹1,818.00
52W Range
₹1,497.35 – ₹1,961.80
Volume
30.74 L
Market Cap
₹4,34,920 Cr
P/E Ratio
13.09
Dividend Yield
+0.01%
Headquarters
Ahmedabad, India
Incorporated
18 Jun 1989
Employees
9,336
Website
www.arogyam-pharmaceuticals-ltd.example
Arogyam Pharmaceuticals Ltd operates in the pharmaceuticals space within the broader healthcare sector, serving customers across India with a focus on operational efficiency and steady capacity expansion.
| Name | Ownership | Business |
|---|---|---|
| Arogyam Pharma Services Pvt Ltd | 100% | Support operations for the pharmaceuticals business |
Among the established players in the pharmaceuticals segment, with a diversified customer base and a track record of steady execution.
Sunita Oberoi
Chairman (Non-Executive, Promoter)
Since 13 Apr 2003
Meenal Nair
Managing Director & CEO
Since 03 Feb 2006
Vivek Bhatt
Chief Financial Officer
Since 12 Oct 2009
| Name | Designation | Since |
|---|---|---|
| Sunita Oberoi | Chairman (Non-Executive, Promoter) | 13 Apr 2003 |
| Meenal Nair | Managing Director & CEO | 03 Feb 2006 |
| Rajiv Nair | Independent Director | 17 Mar 2020 |
| Rohan Vasudeva Iyer | Independent Director | 13 Feb 2021 |
| Sanjay Kapoor | Independent Director | 17 Jun 2022 |
| Karan Verma | Independent Director | 13 Jul 2023 |
18 Jun 1989
Incorporation
Arogyam Pharmaceuticals Ltd incorporated as a private limited company in Ahmedabad.
05 Aug 2001
Public Listing
Listed on NSE via IPO to fund capacity expansion.
12 May 2013
Growth Milestone
Crossed a key annual revenue milestone, reflecting steady growth in the healthcare business.
| Metric | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹36,683 Cr | ₹39,646 Cr | ₹46,032 Cr | ₹39,123 Cr | ₹43,056 Cr | ₹46,026 Cr | ₹52,814 Cr | ₹43,824 Cr |
| Revenue Growth (YoY) | +11.38% | +11.46% | +11.56% | +8.40% | +9.79% | +11.20% | +10.84% | +8.33% |
| Operating Profit | ₹8,217 Cr | ₹8,770 Cr | ₹10,546 Cr | ₹9,022 Cr | ₹9,877 Cr | ₹10,885 Cr | ₹12,755 Cr | ₹10,338 Cr |
| Operating Margin | +22.40% | +22.12% | +22.91% | +23.06% | +22.94% | +23.65% | +24.15% | +23.59% |
| EBITDA | ₹10,051 Cr | ₹10,752 Cr | ₹12,848 Cr | ₹10,978 Cr | ₹12,030 Cr | ₹13,186 Cr | ₹15,395 Cr | ₹12,529 Cr |
| EBITDA Margin | +27.40% | +27.12% | +27.91% | +28.06% | +27.94% | +28.65% | +29.15% | +28.59% |
| Profit Before Tax | ₹8,305 Cr | ₹8,865 Cr | ₹10,656 Cr | ₹9,116 Cr | ₹9,980 Cr | ₹10,996 Cr | ₹12,881 Cr | ₹10,443 Cr |
| Net Profit | ₹6,229 Cr | ₹6,649 Cr | ₹7,992 Cr | ₹6,837 Cr | ₹7,485 Cr | ₹8,247 Cr | ₹9,661 Cr | ₹7,832 Cr |
| Net Profit Margin | +16.98% | +16.77% | +17.36% | +17.48% | +17.38% | +17.92% | +18.29% | +17.87% |
| EPS (₹) | 25.96 | 27.71 | 33.31 | 28.49 | 31.20 | 34.37 | 40.26 | 32.64 |
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹1,07,423 Cr | ₹1,22,893 Cr | ₹1,39,361 Cr | ₹1,56,643 Cr | ₹1,81,019 Cr |
| Total Expenses | ₹84,864 Cr | ₹96,471 Cr | ₹1,08,702 Cr | ₹1,21,226 Cr | ₹1,38,480 Cr |
| Operating Profit | ₹22,559 Cr | ₹26,422 Cr | ₹30,659 Cr | ₹35,418 Cr | ₹42,538 Cr |
| Operating Profit Margin | +21.00% | +21.50% | +22.00% | +22.61% | +23.50% |
| Profit Before Tax | ₹22,924 Cr | ₹26,840 Cr | ₹31,133 Cr | ₹35,950 Cr | ₹43,154 Cr |
| Net Profit | ₹17,193 Cr | ₹20,130 Cr | ₹23,350 Cr | ₹25,501 Cr | ₹32,230 Cr |
| EPS (₹) | 71.66 | 83.90 | 97.32 | 106.28 | 134.33 |
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Total Assets | ₹1,33,148 Cr | ₹1,59,831 Cr | ₹1,93,154 Cr | ₹2,27,474 Cr | ₹2,69,348 Cr |
| Total Liabilities | ₹46,511 Cr | ₹56,083 Cr | ₹69,559 Cr | ₹82,203 Cr | ₹96,682 Cr |
| Total Equity | ₹86,637 Cr | ₹1,03,748 Cr | ₹1,23,595 Cr | ₹1,45,271 Cr | ₹1,72,666 Cr |
| Total Debt | ₹16,187 Cr | ₹19,771 Cr | ₹26,301 Cr | ₹31,359 Cr | ₹36,249 Cr |
| Cash & Equivalents | ₹11,402 Cr | ₹12,698 Cr | ₹13,999 Cr | ₹16,068 Cr | ₹18,523 Cr |
| Net Worth | ₹86,637 Cr | ₹1,03,748 Cr | ₹1,23,595 Cr | ₹1,45,271 Cr | ₹1,72,666 Cr |
| Debt to Equity | 0.19 | 0.19 | 0.21 | 0.22 | 0.21 |
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹20,953 Cr | ₹24,431 Cr | ₹28,228 Cr | ₹30,983 Cr | ₹38,565 Cr |
| Investing Cash Flow | ₹-6,982 Cr | ₹-7,988 Cr | ₹-9,058 Cr | ₹-10,182 Cr | ₹-11,766 Cr |
| Financing Cash Flow | ₹-12,965 Cr | ₹-15,147 Cr | ₹-17,868 Cr | ₹-18,733 Cr | ₹-24,344 Cr |
| Free Cash Flow | ₹13,970 Cr | ₹16,443 Cr | ₹19,169 Cr | ₹20,801 Cr | ₹26,799 Cr |
| Net Cash Flow | ₹1,005 Cr | ₹1,296 Cr | ₹1,302 Cr | ₹2,069 Cr | ₹2,455 Cr |
P/B Ratio
2.52
Price / Sales
2.34
Debt to Equity
0.21
EPS (TTM)
₹138.48
Book Value / Share
₹719.63
Current Ratio
1.55
ROE
+19.24%
ROCE
+20.99%
ROA
+12.34%
Operating Margin
+23.61%
Net Profit Margin
+17.89%
Revenue Growth
+15.01%
Profit Growth
+19.92%
Arogyam Pharmaceuticals Ltd announces strategic order in healthcare segment
The company shared an update on its ongoing strategic order initiative aimed at strengthening its position in the healthcare sector.
Board approves unaudited financial results for Q1 FY27
The Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Q1 FY27 earnings conference call - transcript and recording
Transcript and audio recording of the earnings call held with analysts following the Q1 FY27 results.
Intimation of Board Meeting on August 14, 2026
Intimation that the Board will meet to consider Q1 FY27 unaudited financial results.
Investor presentation - FY26 performance and FY27 outlook
Presentation covering FY26 annual performance and FY27 growth outlook shared at the investor day.
Arogyam Pharmaceuticals Ltd outlines FY27 growth plan
Management outlined its FY27 growth roadmap, including planned capex and new healthcare initiatives.
Board approves audited results for FY26 and recommends final dividend
The Board approved the audited FY26 results and recommended a final dividend of Rs 0.20 per share.
Update on pharmaceuticals operations
The company provided an operational update on its pharmaceuticals business.
| Type | Action Date | Ex Date | Details | Value |
|---|---|---|---|---|
| Board Meeting | 24 Oct 2026 | — | Board meeting scheduled to consider Q2 FY27 unaudited financial results. | — |
| AGM | 25 Jul 2026 | — | Annual General Meeting held virtually to approve FY26 accounts and final dividend. | — |
| Board Meeting | 14 Aug 2026 | — | Board meeting to approve unaudited financial results for Q1 FY27. | — |
| Final Dividend | 28 Apr 2026 | 19 May 2026 | Final dividend for FY26 recommended by the Board and approved at the AGM. | Rs 0.20 per share |
| Interim Dividend | 08 Nov 2025 | 21 Nov 2025 | Interim dividend for FY26 approved by the Board. | Rs 0.08 per share |
| Final Dividend | 22 Apr 2025 | 13 May 2025 | Final dividend for FY25 approved at the AGM. | Rs 0.17 per share |
| Date | Party | Quantity | Price | Value (₹ Cr) | Type |
|---|---|---|---|---|---|
| 18 Sept 2026 | Kotak Emerging Equity Fund | 47.99 L | ₹1,794.52 | 861.14 | Buy |
| 22 Aug 2026 | Meenal Family Office | 23.99 L | ₹1,758.27 | 421.87 | Sell |
| Date | Party | Quantity | Price | Value (₹ Cr) | Type |
|---|---|---|---|---|---|
| 12 Sept 2026 | Morgan Stanley Asia (Singapore) Pte | 71.98 L | ₹1,785.46 | 1,285.19 | Buy |
| Date | Party | Quantity | Price | Value (₹ Cr) | Type |
|---|---|---|---|---|---|
| 20 Aug 2026 | Meenal Nair (Managing Director & CEO) | 1.20 L | ₹1,740.14 | 20.88 | Buy |
| 15 May 2026 | Vivek Bhatt (CFO) | 71,981 | ₹1,667.64 | 12.00 | Sell |
Shares moved higher amid positive sentiment across the healthcare sector.
KuberaNow · Priya Nair
Revenue grew 8.3% YoY on steady execution.
KuberaNow · Aarav Mehta
Management guided for continued double-digit revenue growth.
KuberaNow · Priya Nair
Full-year net profit rose on margin expansion and higher volumes.
KuberaNow · Priya Nair
Multiple brokerages raised target prices citing an improving business mix.
KuberaNow · Priya Nair
| Company | Market Cap | Price | P/E | P/B | ROE | Rev. Growth | Profit Growth |
|---|---|---|---|---|---|---|---|
| BHOOMIBhoomi Power Infra Ltd | ₹5,43,655 Cr | ₹827.87 | 11.16 | 2.87 | +21.73% | +12.58% | +23.93% |
| ARAVALLIAravalli Bank Ltd | ₹2,66,542 Cr | ₹2,140.98 | 16.80 | 3.14 | +24.76% | +15.75% | +21.41% |
| SATPURASatpura Cement Ltd | ₹7,52,103 Cr | ₹2,870.32 | 10.38 | 2.15 | +15.75% | +12.22% | +20.50% |
| SHIVALIKShivalik Capital Ltd | ₹4,02,475 Cr | ₹1,114.52 | 12.64 | 2.91 | +13.83% | +17.31% | +15.34% |
| TRINETRATrinetra Engineering Ltd | ₹4,57,251 Cr | ₹893.58 | 10.87 | 2.03 | +23.51% | +12.31% | +22.62% |
RSI (14)
17.32
MACD
-32.30
MACD Signal
-27.45
MACD Histogram
-4.85
SMA 20
₹1,837.08
SMA 50
₹1,800.34
SMA 100
₹1,726.86
SMA 200
₹1,598.26
EMA 20
₹1,829.79
EMA 50
₹1,809.52
Pivot Point
₹1,787.47
Resistance Levels
Support Levels
Computed from the last 30 trading sessions ended 2026-09-24; pivot and support/resistance use the classic pivot formula on that day's OHLC.
Overall Stock Health
Out of 100, weighted across 5 factors
